Literature DB >> 3456827

Correlation between chromosomal abnormalities and blast phenotype in the blast crisis of Ph-positive CGL.

L Parreira, L Kearney, F Rassool, V B Babapulle, E Matutes, A Parreira, J Tavares de Castro, J M Goldman, D Catovsky.   

Abstract

We carried out cytogenetic analysis in 23 patients with Ph-positive chronic granulocytic leukemia in blast crisis. In all cases the type of blast cell was characterized by cytochemistry, immunologic markers, and ultrastructural studies. Twelve cases were classified as myeloid transformation, six as lymphoid, two as mixed (lymphoid and myeloid), and two were unclassifiable. Duplication of Ph was the most frequent abnormality in the whole series. Trisomy 8, i(17q) and trisomy 19 were seen only in patients with myeloid blast crisis (53%, 30%, and 23%, respectively). Our findings suggest that the nature of additional chromosome abnormalities arising in blasts with features of myeloid differentiation are different from those in blasts showing lymphoid differentiation.

Entities:  

Mesh:

Year:  1986        PMID: 3456827     DOI: 10.1016/0165-4608(86)90134-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

Authors:  M Horita; E J Andreu; A Benito; C Arbona; C Sanz; I Benet; F Prosper; J L Fernandez-Luna
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

Review 2.  Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Authors:  Anna M Eiring; Michael W Deininger
Journal:  Genome Biol       Date:  2014-09-17       Impact factor: 13.583

3.  Prognostic significance of isochromosome 17q in hematologic malignancies.

Authors:  Dorota Koczkodaj; Justyna Muzyka-Kasietczuk; Sylwia Chocholska; Monika Podhorecka
Journal:  Oncotarget       Date:  2021-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.